Genelux (GNLX) Stock: Buy, Sell, or Hold?
GNLX - Genelux Corporation Common Stock
$2.00
0.02 (1.01%)
▲
5d:
-17.36%
30d:
-17.7%
90d:
-32.2%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 04, 2026
10d
Get Alerted When GNLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GNLX is down 17.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GNLX is down 17.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GNLX is currently trading at $2.00, which is considered oversold relative to its 30-day fair value range of $2.29 to $2.61.
Technical Outlook: Technically, GNLX is in a strong downtrend. Immediate support is located at $1.90, while resistance sits at $2.61.
Market Sentiment: GNLX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $18.83 (+841.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GNLX is in a strong downtrend. Immediate support is located at $1.90, while resistance sits at $2.61.
Market Sentiment: GNLX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $18.83 (+841.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.29 -
$2.61
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 841.7% below Wall St target ($18.83)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.29 -
$2.61
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.63
(31.7%)
Support & Resistance Levels
Support Level
$1.90
Resistance Level
$2.61
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.66
Wall Street Target
$18.83
(+841.7%)
Revenue Growth (YoY)
-95.3%
Share & Embed Analysis
Last updated: October 23, 2026 10:20 PM ET
Data refreshes hourly during market hours. Next update: 11:20 PM
Data refreshes hourly during market hours. Next update: 11:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GNLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 58 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
PVLA
Palvella Therapeutics, I… |
STRONG BUY
15 analysts |
$231 | 60 HOLD |
